Drugs / Maxy-G34
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00501332 Comparator | Jul 2007 → ? | breast cancer, neutropenia | Maxygen Holdings Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maxy-G34 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00501332 ↗ |
| Modality | Protein / enzyme biologic | “pegylated recombinant human G-CSF” NCT00501332 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT00501332 ↗ |